SEC Form 4/A · accession 0001393905-18-000022
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
PORTAGE BIOTECH INC.
Other
Period of report
Jan 19, 2018
Accepted (ET)
Jan 25, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2,F4 | Jan 19, 2018 | S | 35,119 | $30.03 | D | 78,771 | D | |
| Common SharesF3,F4 | Jan 23, 2018 | S | 24,277 | $33.15 | D | 54,494 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 - $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 - $33.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The reduction in shares reflects the sale of shares reported upon and the dividend distribution of 6,102,729 shares of common stock completed on January 16, 2018.